The hemodynamically significant PDA in preterm infants: echocardiographic criteria, the shift toward conservative/selective treatment, and pharmacological vs surgical/device closure — built on West Midlands Neonatal Guidelines 2025–28 and current PDA trials
The ductus arteriosus normally closes soon after birth, but in preterm infants it frequently stays open. A large left-to-right shunt through a persistent PDA increases pulmonary blood flow and steals systemic perfusion, and has been associated with BPD, IVH, NEC, and death. However, many PDAs close spontaneously and treatment has not consistently improved outcomes, so practice has shifted toward conservative management with selective, targeted treatment of the genuinely significant, symptomatic PDA.
Over-treatment (aggressive early closure of all PDAs) exposes infants to drug toxicity and surgery without proven benefit, while ignoring a truly significant PDA risks pulmonary and systemic harm. The skill is identifying which PDA actually needs treatment and when.
| Term | Definition |
|---|---|
| PDA | Persistent patency of the ductus arteriosus after birth. |
| hsPDA | Hemodynamically significant PDA — a large shunt causing pulmonary overcirculation/systemic steal with clinical/echo features. |
| Left-to-right shunt | Flow from aorta to pulmonary artery through the duct (pulmonary overcirculation). |
| Ductal steal | Diastolic runoff reducing systemic (including cerebral, mesenteric, renal) perfusion. |
| Conservative management | Supportive care allowing spontaneous closure without targeted PDA drugs/surgery. |
COX inhibitors promote ductal constriction; paracetamol is an alternative. Choice and course per local policy.
| Agent | Notes | Key cautions |
|---|---|---|
| Ibuprofen | Common first-line COX inhibitor; oral or IV per policy. | Renal impairment, oliguria, bleeding, NEC, thrombocytopenia. |
| Indomethacin | COX inhibitor; also studied for IVH prophylaxis. | Renal/GI/cerebral perfusion effects; similar contraindications. |
| Paracetamol (acetaminophen) | Alternative where COX inhibitors are contraindicated. | Monitor liver function; efficacy comparable in studies. |
Avoid COX inhibitors with significant renal impairment, active bleeding, NEC, or marked thrombocytopenia; never attempt closure if the lesion is duct-dependent. Section 8+ below gives Baylor Ed. 33's exact doses, intervals, contraindications and stopping rules — still confirm them against the Neonatal Formulary and local policy before use.
This is the protocol behind the general advice above: which ducts qualify for treatment, with what doses, and when to stop.
By 7–10 days of life, evaluate for clinical signs of a haemodynamically significant duct: murmur, widened pulse pressure, hyperdynamic precordium, hypotension, significant respiratory support, oliguria, feeding intolerance, pulmonary oedema on the chest film. If suspicious, obtain an echocardiogram. Pharmacotherapy requires at least two of the four clinical criteria AND at least one echocardiographic criterion:
If the criteria are not met, continue conservative management: fluid restriction to 120–130 mL/kg/day, optimized PEEP, and diuretics for pulmonary oedema. Extreme volume restriction or diuresis is of no benefit and may further impair systemic perfusion. Total fluid above 150–170 mL/kg/day in the first days of life is itself a risk factor for a symptomatic duct in ELBW infants.
For symptomatic infants older than 14 days with an hsPDA and a large left-to-right shunt (left-sided cardiac enlargement) or echo signs of myocardial dysfunction — up to two courses. No benefit has been established for treating an asymptomatic duct, a duct in the first 3 days of life, or a small duct in an infant not needing positive pressure (moderate certainty, strong recommendation). The AAP's 2025 clinical report is explicit that prophylactic or early (<2 weeks) medical closure is not recommended compared with expectant management (Ambalavanan 2025). Feeds need not be withheld in these infants.
| Ibuprofen lysine — first choice | Detail |
|---|---|
| Dosing | First dose 10 mg/kg of birth weight; second dose 5 mg/kg at 24 hours; third dose 5 mg/kg at 48 hours. Put the birth weight on every order — the dose is by birth weight, not current weight. |
| Why it is preferred | As effective as indomethacin, with lower risks of NEC and transient renal insufficiency (moderate certainty, strong recommendation). |
| Contraindications | Active bleeding or infection · platelets <60,000 or coagulopathy · NEC · significant renal dysfunction (creatinine >1.6 mg/dL or urine output <0.6 mL/kg/h) · any lesion needing ductal-dependent flow. |
| Administration | Infuse over 15 minutes through the IV port closest to the insertion site. Not via umbilical catheter — safety has not been evaluated. Incompatible with TPN: if necessary interrupt TPN for 15 minutes and flush with saline or dextrose before and after. |
| Interactions and effects | May displace bilirubin from binding sites, reduce platelet adhesion, and mask signs of infection. May reduce the efficacy of thiazide and loop diuretics, ACE inhibitors and β-blockers. |
| Stopping rules | Withhold the second or third dose if urine output is <0.6 mL/kg/h. If the duct closes or improves markedly 48 hours or more after the first course finishes, no further doses are needed. Trophic feeds may continue during therapy (low certainty, weak recommendation). |
| Indomethacin — if ibuprofen is unavailable (Baylor Table 3-11) | Dose 1 (mg/kg) | Dose 2 (mg/kg) | Dose 3 (mg/kg) |
|---|---|---|---|
| Age at first dose <48 hours | 0.2 | 0.1 | 0.1 |
| 2–7 days | 0.2 | 0.2 | 0.2 |
| Over 7 days | 0.2 | 0.25 | 0.25 |
A Cochrane review (Jasani, Mitra, Shah, December 2022) suggests acetaminophen is likely as effective as ibuprofen (moderate certainty, weak recommendation), but most infants studied were moderately preterm, so it does not generalize to infants below 1000 g or 28 weeks. With unresolved concerns about neurodevelopmental impairment after prenatal and postnatal exposure, Baylor does not recommend routine use — reserve it for case-by-case situations such as a contraindication to NSAIDs.
Described mainly after surgical ligation but reported after device closure too, it affects up to 50% of preterm infants: oxygenation failure and systemic hypotension requiring cardiotropic support, appearing 8–12 hours after the procedure. Anticipate it rather than react to it. Other surgical morbidities include pneumothorax, vocal cord paralysis and thoracic duct injury with chylothorax. Catheter closure is performed by a venous approach and can be done safely below 1000 g when needed; candidacy depends on respiratory support needs and LA/LV enlargement, decided with cardiology and the catheterization team.
| Time after closure | What is driving the instability | What to do |
|---|---|---|
| 0–2 hours | Increased LV afterload once the low-resistance shunt is gone, with decreased LV preload | Fluid resuscitation, with or without milrinone |
| 2–4 hours | Inadequate adrenal stress response; progressively rising LV afterload; systemic inflammatory response | Start hydrocortisone, plus inotropy and milrinone |
| Beyond 4 hours | Diminished LV contractility — systolic and diastolic dysfunction — with left atrial hypertension and pulmonary venous congestion | Start epinephrine; consider diuretics once the blood pressure is stable |
The proposed mechanisms are a systemic inflammatory response with capillary leak, and a fall in shortening and ejection fractions alongside a rising SVR and a sudden drop in preload. The preterm myocardium simply cannot adapt to the abrupt afterload increase — which is why the first two hours respond to volume and the later hours need inotropy rather than more fluid.
| Parameter | When | Action |
|---|---|---|
| Clinical signs (pulses, precordium, respiratory) | Ongoing | Detect significance/response. |
| Echocardiography | At diagnosis and after treatment | Confirm closure/persistence; exclude CHD. |
| Renal function/urine output/platelets | During COX inhibitor | Watch for toxicity; hold if oliguria/bleeding. |
| Abdominal signs | During treatment | Watch for NEC. |
| Post-ligation hemodynamics | After surgery | Manage post-ligation syndrome. |
| Mistake | Why it harms | Better practice |
|---|---|---|
| Treating every PDA. | Drug/surgery risk, no benefit. | Treat significant, symptomatic PDA only. |
| Relying on the murmur. | Poor marker of significance. | Confirm with echocardiography. |
| COX inhibitor with contraindication. | Renal/GI/bleeding harm. | Check renal/platelets/NEC; use paracetamol if needed. |
| Closing a duct-dependent lesion. | Catastrophic collapse. | Exclude duct-dependent CHD first. |
| Ignoring post-ligation instability. | Missed LV dysfunction. | Anticipate and manage proactively. |